Legal Representation
Attorney
Bridget H. Labutta
USPTO Deadlines
Application History
50 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 26, 2023 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jun 26, 2023 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Feb 7, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Feb 7, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Feb 7, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Dec 3, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 2, 2022 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Dec 2, 2022 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Nov 22, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 22, 2022 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| May 27, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 25, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| May 25, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| May 25, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| May 25, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 25, 2022 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| May 25, 2022 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Feb 2, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Feb 2, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Feb 2, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jan 13, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jan 13, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jan 13, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jan 5, 2022 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Jan 5, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jan 5, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jan 5, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jan 5, 2022 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Nov 19, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 17, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 17, 2021 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Nov 17, 2021 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| May 27, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 25, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 25, 2021 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| May 25, 2021 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Feb 25, 2021 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Feb 25, 2021 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Feb 25, 2021 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Dec 1, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 27, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 27, 2020 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Nov 27, 2020 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| May 26, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Mar 31, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 31, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 11, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 25, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 20, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 22, 2020 | ALIE | A | ASSIGNED TO LIE | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Oligonucleotide compounds for use in the targeted delivery of RNAi therapy; Pharmaceutical preparations for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Chemical compounds in the form of a molecular nanoparticle complex that act as a platform for the delivery of RNA-based drugs to biological cells; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; research and development of pharmaceutical preparations for the treatment of liver-based disorders; research and development of oligonucleotide compounds for targeted gene silencing; scientific research and development; scientific investigations for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Design Mark
The mark consists of the word "DICERNA" above the word "PHARMACEUTICALS" in stylized blue letters on a white background.
Color Claim
The color(s) blue and white is/are claimed as a feature of the mark.
Classification
International Classes
005
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"PHARMACEUTICALS"